Ryan Caezar C David1, Sasan Moghimi1, Jiun L Do1, Huiyuan Hou1, James Proudfoot1, Linda M Zangwill1, Alireza Kamalipour1, Takashi Nishida1, Carlos Gustavo De Moraes2, Christopher A Girkin3, Jeffrey M Liebmann2, Robert N Weinreb4. 1. From the Hamilton Glaucoma Center (R.C.C.D., S.M., J.L.D., H.H., J.P., L.M.Z., A.K., T.N., R.N.W.), Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California. 2. Bernard and Shirlee Brown Glaucoma Research Laboratory (C.G.D.M., J.M.L.), Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. 3. and the Bernard School of Medicine (C.A.G.), University of Alabama-Birmingham, AL, United States. 4. From the Hamilton Glaucoma Center (R.C.C.D., S.M., J.L.D., H.H., J.P., L.M.Z., A.K., T.N., R.N.W.), Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California, San Diego, La Jolla, California. Electronic address: rweinreb@health.ucsd.edu.
Abstract
PURPOSE: To investigate the characteristics and rate of central visual field loss after optic disc hemorrhage (DH). DESIGN: Prospective cohort study. METHODS: Three hundred forty-three eyes of 220 subjects who had ≥3 years of follow-up with a minimum of 5 visits with 10-2 and 24-2 visual field (VF) were recruited. Rates of 10-2 mean deviation (MD) loss in each hemifield and predefined zones were compared using linear mixed-effects models in DH and non-DH eyes. Clustered pointwise regression analysis was also used to define central VF progressors and compared with 24-2 VF loss using guided progression analysis. RESULTS: Thirty-nine eyes with DH and 304 eyes without DH had a mean follow-up of 5.2 years. Eyes with DH had rates of 10-2 MD loss that were 3 times faster than non-DH eyes (mean difference -0.36 dB/year [95% confidence interval 0.54-0.18]; P < .001) and were 3.7 times more likely to progress (P = .002). A larger proportion of glaucomatous eyes showed central VF progression rather than peripheral VF progression in the DH group (30.8% vs. 20.5%) compared with the non-DH group (10.9% vs. 9.2%). In early glaucoma, the rate of 10-2 MD loss was 5.5 times faster in DH eyes than in non-DH eyes (P < .001). Superonasal and superotemporal central VF regions progressed more rapidly than other regions, especially in DH eyes. CONCLUSION: Central VF loss is accelerated in glaucoma eyes with DH and it corresponds topographically to the DH location. In patients with glaucoma with DH, one should consider supplementing 10-2 VFs with 24-2 VFS to monitor the disease.
PURPOSE: To investigate the characteristics and rate of central visual field loss after optic disc hemorrhage (DH). DESIGN: Prospective cohort study. METHODS: Three hundred forty-three eyes of 220 subjects who had ≥3 years of follow-up with a minimum of 5 visits with 10-2 and 24-2 visual field (VF) were recruited. Rates of 10-2 mean deviation (MD) loss in each hemifield and predefined zones were compared using linear mixed-effects models in DH and non-DH eyes. Clustered pointwise regression analysis was also used to define central VF progressors and compared with 24-2 VF loss using guided progression analysis. RESULTS: Thirty-nine eyes with DH and 304 eyes without DH had a mean follow-up of 5.2 years. Eyes with DH had rates of 10-2 MD loss that were 3 times faster than non-DH eyes (mean difference -0.36 dB/year [95% confidence interval 0.54-0.18]; P < .001) and were 3.7 times more likely to progress (P = .002). A larger proportion of glaucomatous eyes showed central VF progression rather than peripheral VF progression in the DH group (30.8% vs. 20.5%) compared with the non-DH group (10.9% vs. 9.2%). In early glaucoma, the rate of 10-2 MD loss was 5.5 times faster in DH eyes than in non-DH eyes (P < .001). Superonasal and superotemporal central VF regions progressed more rapidly than other regions, especially in DH eyes. CONCLUSION: Central VF loss is accelerated in glaucoma eyes with DH and it corresponds topographically to the DH location. In patients with glaucoma with DH, one should consider supplementing 10-2 VFs with 24-2 VFS to monitor the disease.
Authors: Jesse Richman; Luciano L Lorenzana; Dara Lankaranian; Jyoti Dugar; Jason R Mayer; Sheryl S Wizov; George L Spaeth Journal: Ophthalmic Epidemiol Date: 2010-06 Impact factor: 1.648
Authors: John L Keltner; Chris A Johnson; Douglas R Anderson; Richard A Levine; Juanjuan Fan; Kimberly E Cello; Harry A Quigley; Donald L Budenz; Richard K Parrish; Michael A Kass; Mae O Gordon Journal: Ophthalmology Date: 2006-09 Impact factor: 12.079
Authors: Donald C Hood; Ali S Raza; Carlos Gustavo V de Moraes; Jeffrey M Liebmann; Robert Ritch Journal: Prog Retin Eye Res Date: 2012-09-17 Impact factor: 21.198
Authors: Aakriti G Shukla; Portia E Sirinek; C Gustavo De Moraes; Dana M Blumberg; George A Cioffi; Alon Skaat; Christopher A Girkin; Robert N Weinreb; Linda M Zangwill; Donald C Hood; Jeffrey M Liebmann Journal: J Glaucoma Date: 2020-06 Impact factor: 2.503
Authors: C Gustavo De Moraes; Donald C Hood; Abinaya Thenappan; Christopher A Girkin; Felipe A Medeiros; Robert N Weinreb; Linda M Zangwill; Jeffrey M Liebmann Journal: Ophthalmology Date: 2017-05-24 Impact factor: 12.079
Authors: Alireza Kamalipour; Sasan Moghimi; Huiyuan Hou; James A Proudfoot; Takashi Nishida; Linda M Zangwill; Robert N Weinreb Journal: Am J Ophthalmol Date: 2021-11-19 Impact factor: 5.488